CTMX vs PH · rev $138.1M vs P/E 28, rev $19.85B
CytomX Therapeutics Inc (CTMX) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
CTMX currently screens at market cap $653.1M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the CTMX and PH stock pages for the full models.
Not investment advice.